Futai Pharmaceutical's trading volume on February 23rd was $599 million, ranking 190th among U.S. stocks on that day.

K-LinePoet · 2026-02-24T10:48:20+00:00

On February 23, 2026, biotechnology company Foute Pharmaceutical (VRTX) had a trading volume of $599 million, ranking 190th among U.S. stocks on that day. The trading volume increased by 25.17% compared to the previous day, with a daily trading volume of 1.2407 million shares.Foute Pharmaceutical (VRTX) rose 0.86% on February 23, 2026, closing at $481.01. The stock declined 2.13% over the past 5 trading days, increased 2.36% for the entire month of February, and has gained 6.10% since the beginning of the year. Over the past 52 weeks, it has decreased by 0.67%.If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to the present (this also applies to companies listed for less than 1 month or fewer than 5 trading days).| Foute Pharmaceutical (VRTX) | Trading Volume / USD | Change in Trading Volume from Yesterday | Trading Volume || --- | --- | ---

K-LinePoet

2026-02-24 10:48:20

On February 23, 2026, biotechnology company Vertex Pharmaceuticals (VRTX) had a trading volume of $599 million, ranking 190th among U.S. stocks that day. The trading volume increased by 25.17% compared to the previous day, with a total of 1.2407 million shares traded.

Vertex Pharmaceuticals (VRTX) rose 0.86% on February 23, 2026, closing at $481.01. The stock has fallen 2.13% over the past 5 trading days, increased 2.36% for the entire month of February, gained 6.10% year-to-date, and declined 0.67% over the past 52 weeks.

If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to now (this also applies to listings less than 1 month or fewer than 5 trading days).

Vertex Pharmaceuticals (VRTX)	Trading Volume / USD	Change from Previous Day	Shares Traded
February 23, 2026	$599 million	+25.17%	1.2407 million
February 20, 2026	$478 million	-12.52%	1.0066 million
February 19, 2026	$547 million	-30.26%	1.1658 million
February 18, 2026	$784 million	-4.93%	1.663 million
February 17, 2026	$825 million	-42.72%	1.7214 million

Vertex Pharmaceuticals Incorporated was founded in 1989 in Massachusetts. It is a global biotechnology company dedicated to scientific innovation, aiming to create transformative medicines for individuals with serious diseases, especially in specialized markets. The company has developed approved therapies for conditions such as cystic fibrosis, sickle cell disease, transfusion-dependent beta-thalassemia, and acute pain. It continues to innovate and advance next-generation clinical and research projects across various serious diseases, including IgA nephropathy and type 1 diabetes.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.